Corbus Plans CRB-913 Phase 1b Obesity Trial Data Presentation at Obesity Week 2026

Bitget2026/10/22 12:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Corbus Pharmaceuticals will present CRB-913 Phase 1b CANYON-1 study data at Obesity Week on November 15, 2026, in National Harbor, Maryland.
The presentation will cover efficacy, safety and tolerability of CRB-913, an oral drug candidate for obesity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corbus Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610220800PRIMZONEFULLFEED9850803) on October 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Corbus Plans CRB-913 Phase 1b Obesity Trial Data Presentation at Obesity Week 2026

You may also like

Crypto prices